Trials / Completed
CompletedNCT04314622
A Study of Supaglutide in Chinese Type 2 Diabetes Patients
A Randomized, Double-Blind, Placebo-controlled Study of Supaglutide on the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy in Chinese Patients With Type 2 Diabetes.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study on the safety, efficacy, pharmacokinetics and pharmacodynamics of Supaglutide dosing weekly and bi-weekly in patients with type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Supaglutide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2020-04-14
- Primary completion
- 2020-10-25
- Completion
- 2021-03-16
- First posted
- 2020-03-19
- Last updated
- 2021-09-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04314622. Inclusion in this directory is not an endorsement.